Clinical Trials Logo

Ovarian Neoplasm clinical trials

View clinical trials related to Ovarian Neoplasm.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05257408 Active, not recruiting - Clinical trials for Peritoneal Neoplasms

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Start date: June 29, 2022
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate progression-free survival (PFS) by blinded independent central review (BICR) in patients treated with intermittent regimen of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.

NCT ID: NCT03667716 Active, not recruiting - Breast Cancer Clinical Trials

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Start date: September 6, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.

NCT ID: NCT03000192 Active, not recruiting - Ovarian Cancer Clinical Trials

HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life

Start date: August 2016
Phase:
Study type: Observational

The purpose of this study is to invite all people diagnosed with cancer who meet the eligibility criteria to complete questionnaires before their treatment begins and at regular intervals over time to assess the impact of cancer and its treatment on people's lives in the short, medium and long term. We will explore a range of factors to determine their role in both recovery of health and well-being and self-management. Although it is known that people who have had cancer are likely to experience a number of physical and psychological problems as a result of the disease and treatment, it is not known what the 'typical' course of recovery of health and well-being looks like, how long it takes and how this can be influenced. We will determine pathways to recovery of health and well-being following cancer diagnosis (initially breast cancer diagnosed <50 years, Non-Hodgkin Lymphoma and gynaecological cancers) and identify what factors influence this. This includes assessing the relative importance of the person's illness, personal attributes, perceived burden of treatment, role of the environment they live in, including health / social care and personal networks of support, and their ability and capacity to self-manage. We will identify who is most at risk of problems and what environmental supports and resources people are able to mobilise to support their self-management. We will also explore who has the confidence and ability to manage during and beyond treatment and what factors influence this and whether this leads to earlier problem resolution and restoration of health and well-being. This knowledge will be used to develop and test future supportive interventions to enhance the rapid recovery of health and well-being - our long term aim being to design ways of helping people with cancer in areas we identify as problematic for them.